



KFIN/CERT13(3)/SEP/2023 Date : October 06, 2023

Mr. Ajay Nadkarni M/s. GlaxoSmithKline Pharmaceuticals Limited Dr. Annie Besant Road Worli, Mumbai-400025.

Sub: Investor Grievance Certificate for the quarter ended September 30, 2023.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended September 30, 2023.

Description of	Opening	Received during the	Attended/Resolved	Pending as on
Complaint	Balance as on	Period 01.07.2023	during the Period	30.09.2023
	01.07.2023	to 30.09.2023	01.07.2023 to	
			30.09.2023	
Non-receipt of	NIL	07	07	NIL
Dividend				
Non-receipt of	NIL	NIL	NIL	NIL
Annual reports				
Non receipt of	NIL	01	01	NIL
shares				
SEBI	NIL	01	01	NIL
Stock Exchange	NIL	18	17	01
Total	NIL	27	26	01

This is for your information and record.

Thanking you,

Yours faithfully For KFin Technologies Limited

Rajitha Cholleti Dy. Vice President

(Formerly known as KFin Technologies Private Limited)

Registered & Corporate Office:

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500032.

CIN: L72400TG2017PLC117649